Skip to main content
Figure 6 | BMC Pulmonary Medicine

Figure 6

From: Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial

Figure 6

Changes from baseline in exercise endurance and physical activity at Week 3, by baseline physical activity. Changes from baseline in a) exercise endurance time during constant work rate cycle ergometry to symptom limitation at 75% of the maximum work rate, b) daily step count, c) duration of moderate activity >3 metabolic equivalents, and d) energy expenditure at Week 3 were assessed according to baseline physical activity levels (inactive, sedentary, or at least moderately active; ITT population). Data reported as least squares means change from baseline (analysis of covariance) + standard error; Δ = least squares means difference (95% confidence intervals). n = number of patients in each subgroup included in the analyses. *p < 0.05 versus placebo. BID, twice daily; ITT, intent-to-treat.

Back to article page